Transcription
So I'm Ludovic Le Meunier, and I am the CEO of THERYQ. It's a company specialized in the development of radiotherapy flash where your therapy devices. We are a spinoff from another company and we've been created last year, but we have a 10 year experience on this specific topic, we have developed one product, which is called flush knife. This potluck is capable of curate concert in one session of what your therapy. So maybe before going further, maybe I can explain to you what is conventional radiotherapy and what do we do with radiotherapy. So while your therapy use particle loaded with energy to actually try to break the DNA of a tumor, but when you do that, there is a side effect, and you have an impact on the healthy tissue tissue around the tumor. So that's one of the big limitation of commercial radiotherapy. And usually to limit what side effects you apply the treatments in many sessions of several minutes. While we flush radiotherapy, we find a solution to these limits, we apply the same, the same total dose to the tumor, but not in many session of several minutes, but in one session of a fraction of a second. So you patient come back only once to get cured for his concern. So and when you do at usually protect the healthy tissue much more than when you do conventional radiotherapy. So that's the healing evolution of flash radiotherapy. So THERYQ, as developed one product, the first one, which is called Flash knife, so this project is suitable to treat superficial tumors, and also can be used in intraoperative radiotherapy, we did many clinical students successful technical studies, we even treated one patient in 2018. And now we're getting into clinical trial and this system going to be on the market in 2025. So that's the first product that we have developed. Now we have another project. And we have started this project, we started this project last year, we these projects, we will treat every solid tumors anywhere in the body, Flash knife was dedicated to superficial tumors, Flash deep is a new product, we'll be able to treat every solid tumors in one session anywhere in the body. So that's another huge revolution. And how we can do that when we can do that because we have an exclusive agreements with the world leader in a particular acceleration is the CERN in Switzerland, in Geneva. And we have this exclusive agreement to use their specific technology to accelerate electrons in a very short distance. So since we have this agreement, we can go into the development of his new machine that's going to be on the market in 2027. And we are full of hope because it flash knife was a real revolution. This one it's even a bigger revolution. So but beyond vision of THERYQ to be able to be to be like a leader in wire for RV and in Flash radiotherapy is the next few years. So we have partnership with the Lausanne University in Lausanne University Hospital, which is one of how, you know, big partner since a very long time. We work with several Hospital in France, in Germany, in Portugal, in in the UK soon, and we are trying to get into the US. So that's why we're here. And of course we are trying to raise the money for the second phase of the project. Because it's bigger. It's a bigger system, which still is going to be suitable for installation inside the hospital. But that's why I'm here. It goes in our YRP departments. Usually they do have commercial radiotherapy system, we will install that you know regular boom curves, which is quite common in a radio, draw your therapy department. Well here's with the first machine it's superficial tumor, so it's mostly skin cancer. And you know, I talk a little bit about it, you can use a system intraoperative radiotherapy, so usually usually you can you have surgery, you will remove the trimmer, and while the body of the patient is open, you come with Flash knife or a system like that. And then you just send radiation so you kill the tumor but the cancer but you left it insides the wounds I would say. So that's one of the limits of flush knife with the other one we flush deep, then you will be able to tweet every solid tumors. And one thing that I did that didn't work on Pfizer's on Feist, yes or didn't put strain on it. With the new system, we'll be able to treat the 30 to 40% of tumors, which don't have therapeutic alternative. We could trade like glioblastoma or pancreatic cancer or pancreatic cancer. And that's a huge plus with the system. You know, it's what it's called in the clinical world. It's the unmet clinical need, and how system will be able to tweet for specific concert. So you know, I use the word revolution, but I'm not kidding. But so he'll one so. So this is our first time at LSI it seems that there are a lot of opportunities to meet investor and that's why we're here. It's a very nice setting. So we're quite happy to be here and we expect to meet many investors in the next few days.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
